These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 21474670)

  • 1. Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion.
    Neri P; Ren L; Azab AK; Brentnall M; Gratton K; Klimowicz AC; Lin C; Duggan P; Tassone P; Mansoor A; Stewart DA; Boise LH; Ghobrial IM; Bahlis NJ
    Blood; 2011 Jun; 117(23):6202-13. PubMed ID: 21474670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Myeloma-Derived MIF in Myeloma Cell Adhesion to Bone Marrow and Chemotherapy Response.
    Zheng Y; Wang Q; Li T; Qian J; Lu Y; Li Y; Bi E; Reu F; Qin Y; Drazba J; Hsi E; Yang J; Cai Z; Yi Q
    J Natl Cancer Inst; 2016 Nov; 108(11):. PubMed ID: 27381622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma.
    Noborio-Hatano K; Kikuchi J; Takatoku M; Shimizu R; Wada T; Ueda M; Nobuyoshi M; Oh I; Sato K; Suzuki T; Ozaki K; Mori M; Nagai T; Muroi K; Kano Y; Furukawa Y; Ozawa K
    Oncogene; 2009 Jan; 28(2):231-42. PubMed ID: 18850009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma.
    Waldschmidt JM; Simon A; Wider D; Müller SJ; Follo M; Ihorst G; Decker S; Lorenz J; Chatterjee M; Azab AK; Duyster J; Wäsch R; Engelhardt M
    Br J Haematol; 2017 Oct; 179(1):36-49. PubMed ID: 28670693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro migratory aberrancies of mesenchymal stem cells derived from multiple myeloma patients only partially modulated by bortezomib.
    Xu X; Yang J; Tang Y; Li J; Zhu Y; Lu H; Fei X
    Int J Clin Exp Pathol; 2014; 7(10):6705-15. PubMed ID: 25400750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.
    Azab AK; Runnels JM; Pitsillides C; Moreau AS; Azab F; Leleu X; Jia X; Wright R; Ospina B; Carlson AL; Alt C; Burwick N; Roccaro AM; Ngo HT; Farag M; Melhem MR; Sacco A; Munshi NC; Hideshima T; Rollins BJ; Anderson KC; Kung AL; Lin CP; Ghobrial IM
    Blood; 2009 Apr; 113(18):4341-51. PubMed ID: 19139079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sphingosine-1-phosphate activates chemokine-promoted myeloma cell adhesion and migration involving α4β1 integrin function.
    García-Bernal D; Redondo-Muñoz J; Dios-Esponera A; Chèvre R; Bailón E; Garayoa M; Arellano-Sánchez N; Gutierrez NC; Hidalgo A; García-Pardo A; Teixidó J
    J Pathol; 2013 Jan; 229(1):36-48. PubMed ID: 22711564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib.
    Podar K; Shringarpure R; Tai YT; Simoncini M; Sattler M; Ishitsuka K; Richardson PG; Hideshima T; Chauhan D; Anderson KC
    Cancer Res; 2004 Oct; 64(20):7500-6. PubMed ID: 15492276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma.
    Hurt EM; Wiestner A; Rosenwald A; Shaffer AL; Campo E; Grogan T; Bergsagel PL; Kuehl WM; Staudt LM
    Cancer Cell; 2004 Feb; 5(2):191-9. PubMed ID: 14998494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells.
    Tai YT; Soydan E; Song W; Fulciniti M; Kim K; Hong F; Li XF; Burger P; Rumizen MJ; Nahar S; Podar K; Hideshima T; Munshi NC; Tonon G; Carrasco RD; Afar DE; Anderson KC
    Blood; 2009 Apr; 113(18):4309-18. PubMed ID: 19196658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acquisition of resistance toward HYD1 correlates with a reduction in cleaved α4 integrin expression and a compromised CAM-DR phenotype.
    Emmons MF; Gebhard AW; Nair RR; Baz R; McLaughlin ML; Cress AE; Hazlehurst LA
    Mol Cancer Ther; 2011 Dec; 10(12):2257-66. PubMed ID: 21980133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding of MMP-9-degraded fibronectin to β6 integrin promotes invasion via the FAK-Src-related Erk1/2 and PI3K/Akt/Smad-1/5/8 pathways in breast cancer.
    Li W; Liu Z; Zhao C; Zhai L
    Oncol Rep; 2015 Sep; 34(3):1345-52. PubMed ID: 26134759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia.
    Yanamandra N; Colaco NM; Parquet NA; Buzzeo RW; Boulware D; Wright G; Perez LE; Dalton WS; Beaupre DM
    Clin Cancer Res; 2006 Jan; 12(2):591-9. PubMed ID: 16428505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transforming growth factor β induces bone marrow mesenchymal stem cell migration via noncanonical signals and N-cadherin.
    Dubon MJ; Yu J; Choi S; Park KS
    J Cell Physiol; 2018 Jan; 233(1):201-213. PubMed ID: 28213973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alkylating agents induce activation of NFkappaB in multiple myeloma cells.
    Baumann P; Mandl-Weber S; Oduncu F; Schmidmaier R
    Leuk Res; 2008 Jul; 32(7):1144-7. PubMed ID: 18083229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of beta1-integrin enhances TGF-beta1-induced collagen expression in epithelial cells via increased alphavbeta3-integrin and Rac1 activity.
    Hayashida T; Jones JC; Lee CK; Schnaper HW
    J Biol Chem; 2010 Oct; 285(40):30741-51. PubMed ID: 20650890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence that β7 Integrin Regulates Hematopoietic Stem Cell Homing and Engraftment Through Interaction with MAdCAM-1.
    Murakami JL; Xu B; Franco CB; Hu X; Galli SJ; Weissman IL; Chen CC
    Stem Cells Dev; 2016 Jan; 25(1):18-26. PubMed ID: 26422691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation.
    Podar K; Tai YT; Lin BK; Narsimhan RP; Sattler M; Kijima T; Salgia R; Gupta D; Chauhan D; Anderson KC
    J Biol Chem; 2002 Mar; 277(10):7875-81. PubMed ID: 11751905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suitable drug combination with bortezomib for multiple myeloma under stroma-free conditions and in contact with fibronectin or bone marrow stromal cells.
    Kikuchi J; Koyama D; Mukai HY; Furukawa Y
    Int J Hematol; 2014 Jun; 99(6):726-36. PubMed ID: 24706190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma.
    Yang Y; Chen Y; Saha MN; Chen J; Evans K; Qiu L; Reece D; Chen GA; Chang H
    Leukemia; 2015 Mar; 29(3):715-26. PubMed ID: 25179733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.